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A B S T R A C T
Background: Cilostazol has been reported to prevent atherosclerotic events in the general population.
However, data have been limited whether there are beneﬁcial effects of cilostazol use on long-term
clinical outcomes after endovascular therapy in hemodialysis (HD) patients with peripheral artery
disease (PAD).
Methods and results: This study consisted of 595 HD patients undergoing endovascular therapy for a
clinical diagnosis of PAD. They were divided into two groups: patients receiving 100 mg cilostazol twice
daily in conjunction with standard therapy (n = 249 patients, cilostazol group) and those not
administered cilostazol (n = 346 patients, control group). A propensity score analysis was performed
to adjust for baseline differences between the two groups. The propensity score-adjusted 10-year event-
free survival rate from major adverse cardiovascular events (MACE) was signiﬁcantly higher in the
cilostazol group than in the control group [58.6% vs. 43.7%, hazard ratio (HR) 0.57; 95% conﬁdence
interval (CI) 0.41–0.79; p = 0.0010]. Notably, the adjusted stroke-free rate was signiﬁcantly higher in the
cilostazol group than in the control group (81.6% vs. 74.7%; HR = 0.48; 95% CI, 0.25–0.92, p = 0.028). Even
after adjusting for other confounders, treatment with cilostazol was an independent predictor for
prevention of MACE and stroke (p = 0.0028 and p = 0.039, respectively).
Conclusions: Cilostazol administration improves long-term clinical outcomes including prevention of
MACE and stroke after endovascular therapy in HD patients with PAD.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
Contents lists available at ScienceDirect
Journal of Cardiology
jo u rn al h om ep age: ww w.els evier .c o m/lo c ate / j j c cIntroduction
Peripheral artery disease (PAD) is related to other vascular
diseases, and is therefore sometimes referred to as a representation
of ‘systemic atherosclerosis’ [1]. Patients with both PAD and
cardiac or cerebrovascular disease have a poor prognosis [2]. On
the other hand, patients receiving hemodialysis (HD) are at a risk* Corresponding author at: Department of Cardiology, Nagoya University
Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550,
Japan. Tel.: +81 52 744 2147; fax: +81 52 744 2157.
E-mail address: hkishii@med.nagoya-u.ac.jp (H. Ishii).
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiolofor systemic atherosclerosis [3,4]. High prevalence of traditional
risk factors is greatly associated with higher rates of atheroscle-
rotic disease in patients with advanced renal disease [5–7]. In such
situations, cardiovascular events including stroke are commonly
seen in patients on HD, with the relative risk of stroke in patients
with end-stage renal disease (ESRD) estimated to be 5–10 times
that of the age-matched general population [8].
Cilostazol, a selective inhibitor of phosphodiesterase 3, inhibits
smooth muscle cell proliferation [9,10]. Chronic treatment with
cilostazol prevents incidence of cardiovascular events including
stroke in patients with atherothrombosis and it also prevents
secondary stroke in Japanese patients [11,12]. However, data
regarding whether such effects extend to subjects receiving HD,gy.
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events, are limited. Therefore, the aim of the present study was to
compare long-term clinical outcomes in HD patients who received
and those who did not receive cilostazol for clinically diagnosed
PAD after revascularization with endovascular therapy (EVT).
Methods
Study population
We performed successful EVT for PAD in 626 HD patients with
end-stage renal failure between January 1999 and December
2010. Eligible patients were retrospectively stratiﬁed by status of
cilostazol treatment: 249 patients receiving 100 mg oral cilostazol
twice daily for more than one month before EVT (cilostazol group)
and 377 patients who did not receive cilostazol (control group). In
advance, 31 patients did not receive cilostazol therapy before EVT,
but initiated oral cilostazol during the follow-up period. Pre-
determined exclusion criteria included an age >80 years and
cancer. All patients received successful procedure deﬁned as a ﬁnal
luminal diameter stenosis <30% without angiographically visual
arterial dissection. They received oral aspirin for at least 7 days
before EVT. The study was conducted in accordance with the
guidelines of the ethics committee in our institution, and was
approved by the hospital ethics committee. Written informed
consent was obtained from each patient.
The primary endpoint was incidence of major adverse
cardiovascular events (MACE), deﬁned as a composite of all-cause
death, new onset or recurrent stroke including cerebral infarction,
cerebral hemorrhage and subarachnoid hemorrhage, and non-fatal
myocardial infarction after EVT. The secondary endpoint was
major adverse limb events (MALE), a composite of target lesion
revascularization (TLR), and major amputation as deﬁned in a
previous paper [13]. Data were obtained from hospital charts and
through telephone interviews with patients conducted by trained
reviewers. Stroke was diagnosed according to clinical signs and/orTable 1
Clinical characteristics.
All patients (n = 595) 
Male (%) 65.7 
Age (years) 67  10 
Diabetes (%) 65.9 
Hypertension (%) 66.6 
Dyslipidemia (%) 27.1 
Smoking (%) 25.7 
Body mass index (kg/m2) 21.2  3.4 
Coronary artery disease (%) 69.9 
Stroke (%) 19.0 
Indication for EVT (%) 
Intermittent claudication 58.8 
Rest pain 15.8 
Ulcer/gangrene 25.4 
Preoperative ABI 0.62  0.28 
ACE inhibitors (%) 23.4 
A-II receptor blockers (%) 48.2 
Warfarin (%) 18.0 
Ticlopidine (%) 59.3 
High-ﬂux membrane (%) 89.1 
Number of lesions 876 
Mean number of lesions (n) 1.5  0.7 
Lesion location (%) 
Iliac artery 29.5 
Femoropopliteal artery 70.5 
TASC classiﬁcation (%) 
Type A + B 75.1 
Type C + D 24.9 
Stent use (%) 66.1 
ABI, ankle brachial pressure index; ACE, angiotensin-converting enzyme; A-II, angiotesymptoms followed by conﬁrmation on computed tomography
and/or magnetic resonance imaging. Diagnosis of myocardial
infarction was based on new ST-segment changes with at least two
contiguous electrocardiographic leads, and a more than two-fold
elevation of creatine kinase level above the maximum peak in the
normal range. To evaluate lower limb peripheral arteries, we
performed follow-up examinations, including Doppler sonogra-
phy, ankle brachial pressure index (ABI) measurement, and/or
clinical observations 3 months after EVT and every 6 months
thereafter. An angiographical evaluation was performed in cases of
an abnormal Doppler waveform >2.4 m/s, worsening clinical
symptoms, depressed ABI, worsening critical limb ischemia, and/or
the need for limb amputation.
Diabetes was deﬁned as a fasting plasma glucose concentration
>126 mg/dl, a randomized plasma glucose concentration
>200 mg/dl, glycated hemoglobin A1c levels 6.5% and/or use
of anti-hyperglycemic treatment. Hypertension was deﬁned as a
systolic blood pressure >160 mmHg, diastolic blood pressure
>90 mmHg, and/or use of anti-hypertensive treatment. Dyslipi-
demia was deﬁned as low-density lipoprotein levels 140 mg/dl,
triglyceride levels 150 mg/dl, and/or high-density lipoprotein
cholesterol levels <40 mg/dl and/or anti-dyslipidemic medication
use. In this study, we deﬁned high-ﬂex membrane as b2
microglobulin clearance 30 ml/min.
Statistical analysis
Statistical analyses were performed using the SPSS 21 software
program (SPSS Inc, Chicago, IL, USA). Continuous variables were
expressed as mean  standard deviation. Between-group differences
were evaluated with the Student t-test for continuous variables and
the chi-square test for categorical variables. Between-group differ-
ences in event-free survival were evaluated using the Kaplan–Meier
method and compared using a log-rank test. Hazard ratios (HR) and
95% conﬁdence intervals (CI) were calculated with a Cox proportional
hazards analysis.Cilostazol (n = 249) Control (n = 346) p-Value
61.8 68.5 0.10
67  10 68  10 0.67
63.9 67.3 0.37
66.7 66.5 0.96
24.5 28.9 0.23
25.3 26.0 0.84
21.3  3.6 21.1  3.2 0.45
66.0 72.8 0.078
16.1 20.8 0.14
0.41
57.0 60.1
18.1 14.2
24.9 25.7
0.63  0.26 0.61  0.30 0.58
24.1 23.1 0.88
50.6 47.1 0.58
19.3 17.3 0.67
61.4 58.4 0.29
92.0 87.0 0.15
348 528
1.4  0.5 1.5  0.7 0.071
0.54
30.7 28.6
69.3 71.4
0.97
75.0 75.2
25.0 24.8
69.8 63.6 0.12
nsin II; EVT, endovascular therapy; TASC, TransAtlantic Inter-Society Consensus.
Table 2
Clinical events.
All patients Cilostazol Control
MACE 173 (29.1%) 50 (20.1%) 123 (35.6%)
All-cause death 149 (25.0%) 42 (16.9%) 107 (30.9%)
MI 19 (3.2%) 6 (2.4%) 13 (3.8%)
Stroke 50 (8.4%) 13 (5.2%) 37 (10.7%)
Infarction 41 (6.9%) 9 (3.6%) 32 (9.2%)
Hemorrhage 9 (1.5%) 4 (1.6%) 5 (1.5%)
MALE 167 (28.1%) 55 (22.1%) 112 (32.4%)
Major amputation 32 (5.4%) 7 (2.8%) 25 (7.2%)
TLR 152 (25.5%) 52 (20.9%) 100 (28.9%)
MACE, major adverse cardiovascular events; MALE, major adverse limb events;
MI, myocardial infarction; TLR, target lesion revascularization.
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two groups, a propensity score analysis was performed using a
multivariate logistic regression model including all the following
baseline covariates: male sex, age, diabetes, hypertension,
dyslipidemia, smoking status, body mass index, previous coronary
artery disease, previous stroke, critical limb ischemia, TransAtlan-
tic Inter-Society Consensus (TASC) type C or D, femoropopliteal
lesion, and stent use. The score was then incorporated into the Cox
proportional hazards model as a covariate. Propensity score-
adjusted event-free survival curves were also constructed. Finally,
to identify independent predictors of the endpoints, we used Cox
multivariable regression models including all covariates with
p < 0.05 on the univariate analysis with propensity score.
Differences were considered statistically signiﬁcant at p < 0.05.
Results
Table 1 shows the patients’ baseline clinical characteristics.
There were no signiﬁcant differences between the two groups.
Although coronary artery disease was more frequent in the control
group, this did not reach statistical signiﬁcance. No signiﬁcant
differences in medications other than cilostazol were seen
between the two groups. When these medications were evaluated
in the multivariate analysis, no signiﬁcant effects in clinical
outcomes were seen (data not shown).
Table 2 shows the incidence of the study endpoints during the
follow-up period (median 41 months, interquartile range: 21–57
months). In the cilostazol group, both MACE and MALE were less
frequent than in the control group. In the Kaplan–Meier analysis,
10-year MACE and MALE event-free rates were signiﬁcantly higher0.0
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Fig. 1. (A) The event-free rate from major adverse cardiovascular events (MACE) during
(MALE) during 10-year follow-up period. (C) The event-free rate from stroke during 10in the cilostazol group than in the control group (58.3% vs. 43.6%,
p = 0.0010, HR = 0.57; 95% CI, 0.41–0.80 and 59.5% vs. 53.5%,
p = 0.0056, HR = 0.63; 95% CI, 0.46–0.87, respectively) (Fig. 1A and
B). The Kaplan–Meier analysis also showed that the cilostazol
group had a higher all-cause stroke-free rate than the control
group (82.0% vs. 74.3%, p = 0.017, HR = 0.46; 95% CI, 0.24–0.88)
(Fig. 1C). Interestingly, however, the incidence of hemorrhagic
stroke was comparable between the two groups (1.6% vs. 1.3%).
Propensity score analysis
The propensity score-adjusted MACE-free rate was 58.6% in the
cilostazol group and 43.7% in the control group (HR = 0.57; 95% CI,
0.41–0.79, p = 0.0010) (Fig. 2A).0.0
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Fig. 2. (A) The propensity score-adjusted event-free rate from major adverse cardiovascular events (MACE) during 10-year follow-up period. (B) The propensity score-
adjusted event-free rate from major adverse limb events (MALE) during 10-year follow-up period. (C) The propensity score-adjusted event-free rate from stroke during 10-
year follow-up period.
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confounders along with the propensity score, cilostazol treatment
(HR 0.58; 95% CI 0.41–0.83; p = 0.0028), ulcer/gangrene prevalence
(HR 1.54; 95% CI 1.08–2.20; p = 0.019), and previous stroke (HR
1.79; 95% CI 1.18–2.70; p = 0.0057) independently predicted MACE
(Table 3). In addition, cilostazol treatment was signiﬁcantly
associated with the prevention of stroke (HR 0.50; 95% CI 0.26–
0.96; p = 0.039).
Propensity score-adjusted MALE-free survival was signiﬁcantly
higher in the cilostazol group than in the control group (59.5% vs.
53.5%, p = 0.0058) (Fig. 2B). After adjustment for other confounders
along with the propensity score, cilostazol treatment (HR 0.64, 95%
CI 0.46–0.88; p = 0.0068), male (HR 1.44, 95% CI 1.01–2.07,
p = 0.044), the prevalence of ulcer/gangrene (HR 1.73, 95% CI
1.23–2.43; p = 0.0016), and stent use (HR 0.63, 95% CI 0.46–0.86;
p = 0.0034) were independent predictors of MALE (Table 3). The
adjusted stroke-free rate during the 10-year follow-up period was
81.6% in the cilostazol group and 74.7% in the control group
(HR = 0.48; 95% CI, 0.25–0.92, p = 0.028) (Fig. 2C).
As shown in Table 3, compared to the control group, the
cilostazol group had a higher event-free rate for MACE, all-cause
death, stroke, MALE, major amputations and TLR.
Discussion
Patients with ESRD have a risk of cardiovascular events that is
20–30 times higher than that of the general population [14]. In
addition, the mortality rate of stroke is also high in patients with
ESRD [15,16]. Renal dysfunction has been shown to independently
predict poor neurological outcomes, and the frequency of stroke
has been shown to be higher in patients with ESRD [17]. Thebeneﬁt of anticoagulation therapy with warfarin for primary stroke
prevention in patients with ESRD is unclear [18]. Although the
prevention of cerebrovascular events and mortality is of clinical
concern, optimal medical therapies have not been established. The
main ﬁnding of the present study was that treatment with
cilostazol had a beneﬁcial effect in terms of preventing adverse
events such as stroke and mortality in HD patients with PAD.
Although it has been previously reported that cilostazol treatment
prevents stroke in non-HD subjects with PAD, it does not improve
the mortality rate in non-HD patients with PAD [11,19]. From the
point of such a view, our ﬁndings regarding HD patients were of
clinical signiﬁcance.
The unique effects of cilostazol include both vasodilation and
inhibition of neointimal proliferation [10,20–22]. We previously
reported that, compared to controls, HD patients with PAD who were
treated with cilostazol had a higher rate of cumulative patency after
EVT [23]. In that study, treatment with cilostazol not only improved
the patency of the lower extremities but also prevented stroke and
adverse events. One study has reported that HD patients have
abnormal platelet function [24,25]. In addition, HD itself may induce
plasma coagulation factors [26]. These mechanisms may cause
thrombus formation in HD patients. In that study, ischemic stroke
was signiﬁcantly prevented in the cilostazol group. By contrast,
bleeding risk also increases in HD patients [6]. Interestingly, cerebral
hemorrhage events were not increased in the cilostazol group in our
study. In other words, administration of cilostazol did not affect
intracranial hemorrhage, which is consistent with the ﬁndings of
previous studies [27]. From such points, our ﬁndings may have
clinical signiﬁcance for the treatment of HD subjects.
Limitations should be considered when interpreting the data of
the study. First, the study had a single-center design with a limited
Table 3
Unadjusted and adjusted hazard ratios of cilostazol for clinical events.
Crude Propensity score-adjusted Risk-adjusted with propensity scorea
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
MACE
Cilostazol use 0.57 (0.41–0.80) 0.0011 0.57 (0.41–0.79) 0.0010 0.58 (0.41–0.83) 0.0028
Male 1.41 (0.95–2.09) 0.086
BMI 0.96 (0.91–1.02) 0.20
Ulcer/gangrene 1.54 (1.08–2.20) 0.019
Previous stroke 1.79 (1.18–2.70) 0.0057
All-cause death
Cilostazol use 0.56 (0.39–0.80) 0.0015 0.55 (0.38–0.78) 0.0010 0.59 (0.38–0.92) 0.020
Male 1.26 (0.81–1.96) 0.29
BMI 0.93 (0.87–0.99) 0.030
Ulcer/gangrene 1.60 (1.01–2.55) 0.048
Stroke
Cilostazol use 0.46 (0.24–0.88) 0.020 0.48 (0.25–0.92) 0.028 0.50 (0.26–0.96) 0.039
Previous stroke 8.05 (4.17–15.55) <0.0001
MI
Cilostazol use 0.64 (0.24–1.68) 0.36 0.63 (0.24–1.66) 0.36 0.79 (0.30–2.09) 0.64
Male 3.10 (1.08–8.84) 0.034
Age 1.04 (0.99–1.08) 0.098
MALE
Cilostazol use 0.63 (0.46–0.87) 0.0056 0.63 (0.46–0.87) 0.0058 0.64 (0.46–0.88) 0.0068
Male 1.44 (1.01–2.07) 0.044
Ulcer/gangrene 1.73 (1.23–2.43) 0.0016
Stent use 0.63 (0.46–0.86) 0.0034
Major amputation
Cilostazol use 0.41 (0.18–0.96) 0.040 0.41 (0.17–0.95) 0.039 0.41 (0.18–0.96) 0.039
Ulcer/gangrene 4.63 (2.27–9.43) <0.0001
TLR
Cilostazol use 0.67 (0.48–0.93) 0.018 0.67 (0.48–0.94) 0.021 0.68 (0.49–0.95) 0.023
Stent use 0.65 (0.48–0.89) 0.0075
BMI, body mass index; CI, conﬁdence interval; HR, hazard ratio; MACE, major adverse cardiovascular events; MALE, major adverse limb events; MI, myocardial infarction;
TLR, target lesion revascularization.
a Adjusting for covariates with p < 0.05 by univariate analysis with propensity score.
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randomized, double-blind, controlled study, although a propensity
score analysis was conducted. The use of propensity-matched
scores may minimize but does not eliminate selection bias. The
scores indicate that the decision to use or not use cilostazol was not
random. Thus, unseen or unmeasured biases in the interpretation
of our results could not be ruled out. Third, the effects of other
speciﬁc drugs and/or drug combinations may have affected the
results. Fourth, recent studies have shown that a good clinical
outcome is achieved in patients with residual renal function even if
they are treated with HD [28,29]. In this study, we did not routinely
evaluate residual renal function. Finally, exercise tolerance was not
assessed in the present study. One report has suggested that
exercise has a beneﬁcial effect on endothelial function in patients
with PAD [30]. This effect may prevent atherothrombotic events.
In HD patients with a clinical diagnosis of PAD, treatment with
cilostazol improved long-term clinical outcomes including the
prevention of both stroke and all-cause mortality. We believe that
administration of cilostazol may have a substantial potential for
improving outcomes due to its effect in preventing atherosclerotic
events in HD patients. A large, prospective, randomized multi-
center study is needed to conﬁrm our ﬁndings.
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